PTGS2 and colon carcinoma: In this sense, mPGES1 inhibitors have demonstrated promising effects in inhibiting colon carcinoma growth (Dixon et al., 2013; Wang et al., 2018; Karpisheh et al., 2019), that may circumvent the in vivo cardiovascular toxicity associated with COX-2 inhibitors.